Using the query waits feature

The Query waits feature is the core ApexSQL Monitor feature and, in most cases, the first step in resolving SQL Server performance issues. Query wait statistics, somewhere referred to as the Response Time Analysis (RTA), is for many less experienced or new DBAs the most complicated part of performance troubleshooting. ApexSQL Monitor’s query wait feature is designed to provide fast and easy insight in the query performance data and thus providing a significant help in identifying the causes of the SQL Server performance issues.

Walkthrough example of configuring a SQL Server database continuous integration pipeline with the ApexSQL DevOps toolkit

In this article, we’ll walk through the process, end to end, on how to set up a CI pipeline. We’ll be using the ApexSQL DevOps toolkit web dashboard but the same principles apply to configuring the toolkit to run with PowerShell scripts and build-server plug-ins.

Also, the concepts and fundamentals are the same for Continuous delivery, although we may add a companion article, covering this process at a later time.

ApexSQL Source Control framework objects inventory

Applies to

ApexSQL Source Control

Summary

This article gives an overview of additional database objects (called framework objects) that ApexSQL Source Control creates on the initial database linking to a source control repository

Description

Dedicated development model

When linking a database using the dedicated development model, the following framework objects will be created:

Title 21 CFR Part 11 (FDA) compliance checklist for ApexSQL Audit

Title 21 CFR Part 11 is the part of Title 21 of the Code of Federal Regulations established by the United States Food and Drug Administration (FDA) as regulation on electronic records and electronic signatures (ERES). Part 11 defines the criteria under which electronic signatures and electronic records are trustworthy, reliable and comparable to paper records

All SQL Server systems that store data which are used in process of making quality decisions or any data to be reported to the FDA must be compliant with Title 21 CFR Part 11